Novità 2012



Area Riservata

Nome utente
Password


 
Non sei registrato?

Reuterin®

Reuterin® è un probiotico a base di fermenti lattici vivi che contiene la sola specie Lactobacillus reuteri DSM 17938. Comunemente presente nella flora batterica dell’uomo, Lactobacillus reuteri colonizza l’intero tratto gastrointestinale, dove svolge un’attività di riequilibrio dell’alterata flora batterica, apportando benefici alla salute dell’individuo.

Reuterin® è sicuro?
Numerosi lavori scientifici pubblicati hanno documentato la sicurezza di Lactobacillus reuteri in bambini e neonati (anche prematuri), in soggetti debilitati ed immunocompromessi.

Come si usa Reuterin®
Reuterin® compresse
Masticare o ingerire 1-2 compresse al giorno prima o dopo i pasti.
Reuterin® sospensione gocce
Assumere 5 gocce al giorno prima o dopo i pasti. Le gocce possono essere ingerite direttamente o miscelate con acqua o bevande fredde di qualsiasi tipo. Nel lattante, Reuterin® può essere miscelato al latte alla temperatura di assunzione (max. 37 °C).
Non miscelare con il latte bollente.
Reuterin® cannucce
Utilizzare una cannuccia al giorno per assumere qualsiasi bevanda fredda. Lactobacillus reuteri è contenuto all’interno della cannuccia perfettamente sigillata in un foglio di alluminio. Aprire il contenitore di alluminio, allungare la cannuccia telescopica ed inserirla nel contenitore della bevanda scelta.

Come conservare Reuterin®
Reuterin® gocce deve essere conservato in frigorifero a 2-8 °C.

Reuterin® compresse e cannucce possono essere conservati a temperatura ambiente
(max 25 °C).

Prima dell’assunzione, controllare la data di scadenza riportata sulla scatola.

Avvertenze: Reuterin® può essere assunto da soggetti intolleranti al lattosio o al glutine.

Confezioni disponibili in farmacia:
10 compresse masticabili
20 compresse masticabili
5 ml sospensione gocce
10 cannucce

Lactobacillus reuteri DSM 17938 è venduto su licenza esclusiva BioGaia (Svezia). Brevetto internazionale.

REFERENZE BIBLIOGRAFICHE

Vivekananda MR, Vandana KL, Bhat KG. Effect of the probiotic Lactobacilli reuteri (Prodentis) in the management of periodontal disease: a preliminary randomized clinical trial. Journal of Oral Microbiology, 2010;2:5344.

Indrio F, Riezzo G, Raimondi F, Bisceglia M, Filannino A, Cavallo L, Francavilla R. Lactobacillus reuteri accelerates gastric emptying and improves regurgitation in infants. Eur J Clin Invest, 2010;epub.

Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol, 2010;299(5):G1087-96.

Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, Roos S, Matteuzzi D. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics, 2010;126(3):e526-33.

Romano C, Ferrau' V, Cavataio F, Iacono G, Spina M, Lionetti E, Comisi F, Famiani A, Comito D. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health, 2010;epub.

Coccorullo P, Strisciuglio C, Martinelli M, Miele E, Greco L, Staiano A. Lactobacillus reuteri (DSM 17938) in Infants with Functional Chronic Constipation: A Double-Blind, Randomized, Placebo-Controlled Study. J Pediatr, 2010; 157(4):598-602.

Romeo MG, Romeo DM, Trovato L, Oliveri S, Palermo F, Cota F, Betta P. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcomes. J Perinat, 2010;epub.

Miniello VL, Brunetti L, Tesse R, Natile M, Armenio L, and Francavilla R. Lactobacillus Reuteri Modulates Cytokines Production in Exhaled Breath Condensate of Children With Atopic Dermatitis. J Ped Gastroenterol Nutr, 2010;50(5):573-6.

Ojetti V, Gigante G, Gabrielli M, Ainora ME, Mannocci A, Lauritano EC, Gasbarrini G, Gasbarrini A. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci, 2010;14(3):163-70.

Egervärn M, Lindmark H, Olsson J, Roos S. Transferability of a tetracycline resistance gene from probiotic Lactobacillus reuteri to bacteria in the gastrointestinal tract of humans. Antonie van Leeuwenhoek, 2010;97:189-200.

Oh PL, Benson AK, Peterson DA, Patil PB, Moriyama EN, Roos S, Walter J. Diversification of the gut symbiont Lactobacillus reuteri as a result of host-driven evolution. The ISME Journal, 2010; 4(3):377-87

Dommels YE, Kemperman RA, Zebregs YE, Draaisma RB, Jol A, Wolvers DA, Vaughan EE, Albers R. Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the human gastrointestinal tract with daily consumption of a low-fat probiotic spread. Appl Environ Microbiol, 2009;75(19):6198-204.

Connolly E. State of the art on research of Lactobacillus reuteri. Minerva Pediatrica, 2009;61(6):634-636.

Egervärn M, Roos S, Lindmark H. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J Appl Microbiol, 2009;107:1658–1668.

Abrahamsson TR, Sinkiewicz G, Jakobsson T, Fredrikson M, Bjorksten B. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. J Pediatr Gastroenterol Nutr, 2009; 49(3):349-54.

Ma X, Mao YK, Wang B, Huizinga JD, Bienenstock J, Kunze WA. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am J Physiol Gastrointest Liver Physiol, 2009 Jan 29.

Schreiber O, Petersson J, Phillipson M, Perry MA, Roos S, Holm L. Lactobacillus reuteri prevents colitis by reducing P-selectin-associated leukocyte and platelet-endothelial cell interactions. Am J Physiol Gastrointest Liver Physiol, 2009;15.

Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol, 2009 Feb 11;9(1):35.

Twetman S, Derawi B, Keller M, Ekstrand K, Yucel-Lindberg T, Stecksen-Blicks C. Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. Acta Odontol Scand, 2009 Feb;67(1):19-24.

Bruni FM, Piacentini GL, Peroni DG, Bodini A, Fasoli E, Boner AL. Cow's milk allergic children can present sensitisation to probiotics. Acta Paediatr, 2009 Feb;98(2):321-3.

Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Care Med, 2009;179:186-93.

Iyer C, Kosters A, Sethl G, Kunnumakkara AB, Aggarwal BB, Versalovic J. Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-KB and MAPK signalling. Cellular Microbiol, 2008;10:1442-52.

 Hüfner E, Britton RA, Roos S, Jonsson H, Hertel C. Global transcriptional response of Lactobacillus reuteri to the sourdough environment. Syst Appl Microbiol, 2008 Oct;31(5):323-38.

Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol, 2008 Oct;74(19):6032-40.

Böttcher MF, Abrahamsson TR, Fredriksson M, Jakobsson T, Björkstén B. Low breast milk TGF-beta2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy. Pediatr Allergy Immunol, 2008 Sep;19(6):497-504.

De Vecchi E, Nicola L, Zanini S, Drago L. In vitro screening of probiotic characteristics of some Italian products. J Chemother, 2008 Jun;20(3):341-7.

Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe, 2008 Jun;14:166-171.

Indrio F, Riezzo G, Raimondi F, Bisceglia M, Cavallo L, Francavilla R. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J Pediatr, 2008 Jun;152(6):801-6.

Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Maurogiovanni G, Bucci N, De Canio A, Indrio F, Cavallo L, Ierardi E, Miniello VL. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter, 2008 Apr;13(2):127-34.

Napoleone E, Di Blasio E, Menghi I, Dall’Olio A , Ionata A, Meffe D, Pinti C, Portolan C. I probiotici nella stipsi funzionale del lattante. Pediatria Preventiva e Sociale, 2008;2:7-16 (in Italian).

Whitehead K, Versalovic J, Roos S, Britton RA. Genomic and genetic characterization of the bile stress response of probiotic Lactobacillus reuteri ATCC 55730. Appl Environ Microbiol, 2008 Mar;74(6):1812-9.

Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiology, 2007 Nov 12;7:101.

Imase K, Tanaka A, Tokunaga K, Sugano H, Ishida H, Takahashi S. Lactobacillus reuteri tablets suppress Helicobacter pylori infection--a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi, 2007 Jul;81(4):387-93.

Wall T, Båth K, Britton RA, Jonsson H, Versalovic J, Roos S. The early response to acid shock in Lactobacillus reuteri involves the ClpL chaperone and a putative cell wall-altering esterase. Appl Environ Microbiol, 2007 Jun;73(12):3924-35.

Arsköld E, Svensson M, Grage H, Roos S, Rådström P, van Niel EW. Environmental influences on exopolysaccharide formation in Lactobacillus reuteri ATCC 55730. Int J Food Microbiol, 2007 May 1;116(1):159-67.

Abrahamsson TR, Jakobsson T, Böttcher MF, Fredrikson M, Jenmalm MC, Björkstén B, Oldaeus G. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol, 2007 May;119(5):1174-80.

Egervärn M, Danielsen M, Roos S, Lindmark H, Lindgren S. Antibiotic susceptibility profiles of Lactobacillus reuteri and Lactobacillus fermentum. J Food Prot, 2007 Feb;70(2):412-8.

Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics, 2007 Jan;119(1):124-30.

Glintborg B, Dawids S, Hasselby JP, Nielsen HW, Nielsen AM. Long term administration of Lactobacillus reuteri (ATCC 55730) has no influence on gastric mucosal inflammation and colonization of Helicobacter pylori in humans. A pilot study. Int J Probiotics Prebiotics, 2006;1:219-24.

Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut, 2006;55:191-96.

Krasse P, Carlsson B, Dahl C, Paulsson A, Nilsson A, Sinkiewicz G. Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed Dent J, 2006;30(2):55-60.

Lionetti E, Miniello VL, Castellaneta SP, Magistá AM, de Canio A, Maurogiovanni G, Ierardi E, Cavallo L, Francavilla R. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther, 2006 Nov 15;24(10):1461-8.

Caglar E, Cildir SK, Ergeneli S, Sandalli N, Twetman S. Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets. Acta Odontol Scand, 2006 Oct;64(5):314-8.

Weizman Z, Alsheikh A. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J Am Coll Nutr, 2006 Oct;25(5):415-9.

Kastner S, Perreten V, Bleuler H, Hugenschmidt G, Lacroix C, Meile L. Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food. Syst Appl Microbiol, 2006 Mar;29(2):145-55.

Dobrogosz WJ. Enhancement of human health with Lactobacillus reuteri. A probiotic, immunobiotic and immunoprobiotic. Nutrafoods, 2005;4(2/3):15-28.

Båth K, Roos S, Wall T, Jonsson H. The cell surface of Lactobacillus reuteri ATCC 55730 highlighted by identification of 126 extracellular proteins from the genome sequence. FEMS Microbiol Lett, 2005 Dec 1;253(1):75-82.

Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health, 2005 Nov 7;4:25.

Connolly E, Abrahamsson T, Björkstén B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Ped Gastr Nutr, 2005;41:489-92.

Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics, 2005 Jan;115(1):5-9.

Eom TH, Oh EY, Kim YH, Lee HS, Jang PS, Kim DU, Kim JT, Lee BC. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J Pediatr 2005;48:986-90.

Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun, 2004;72:5308-14.

Connolly E. Lactobacillus reuteri ATCC 55730 – a clinically proven probiotic. Nutrafoods, 2004;3(1):15-22.

Nikawa H, Makihira S, Fukushima H, Nishimura H, Ozaki Y, Ishida K, Darmawan S, Hamada T, Hara K, Matsumoto A, Takemoto T, Aimi R. Lactobacillus reuteri in bovine milk fermented decreases the oral carriage of mutans streptococci. Int J Food Microbiol, 2004 Sep 1;95(2):219-23.

Peña JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J. Genotypic and phenotypic studies of murine intestinal lactobacilli: species differences in mice with and without colitis. Appl Environ Microbiol, 2004;70:558-68.

Valeur N, Engel P, Carbajal N, Connolly E, Ladefoged K. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol, 2004 Feb;70(2):1176-81.

Casas IA, Dobrogosz WJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad spectrum protection against disease in humans and animals. Microbial Ecology in Health and Disease, 2000;12:247-285.

Wolf BW, Wheeler KB, Ataya DG, Garleb KA. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol, 1998 Dec;36(12):1085-94.

Shornikova AV, Casas IA, Mykkänen H, Salo E, Vesikari T. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J, 1997 Dec;16(12):1103-7.

Shornikova AV, Casas IA, Isolauri E, Mykkänen H, Vesikari T. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr, 1997 Apr;24(4):399-404.

Wolf BW, Garleb K, Ataya, D, Casas IA. Safety and tolerance of Lactobacillus reuteri in healthy adults male subjects. Microbial Ecology Health Disease, 1995;8:41-50.